
    
      Three groups of patients will be randomized to colchicine 0.6 mg PO bis in die (BID) or
      matching placebo:

        1. Paroxysmal atrial fibrillation, pre-ablation

        2. Persistent atrial fibrillation, pre-ablation

        3. Chronic persistent atrial fibrillation
    
  